Livzon Pharmaceutical Group Inc. (SHE: 000513)

Market Cap	30.04B
Revenue (ttm)	11.86B
Net Income (ttm)	2.02B
Shares Out	915.57M
EPS (ttm)	2.19
PE Ratio	16.96
Forward PE	15.47
Dividend	1.35 (3.62%)
Ex-Dividend Date	Jul 8, 2024

Volume	6,176,375
Open	38.55
Previous Close	37.32
Day's Range	37.06 - 38.55
52-Week Range	32.70 - 44.72
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 8,933
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2023, Livzon Pharmaceutical Group's revenue was 12.43 billion, a decrease of -1.58% compared to the previous year's 12.63 billion. Earnings were 1.95 billion, an increase of 2.32%.